Trials / Terminated
TerminatedNCT00811499
A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-371797 (versus placebo) in treating ankylosing spondylitis, and to further evaluate the drug's safety. Approximately 130 patients from the US, Canada, Poland and Hungary will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARRY-371797, p38 inhibitor; oral | multiple dose, single schedule |
| DRUG | Placebo; oral | matching placebo |
| DRUG | Placebo; oral | multiple dose, single schedule |
Timeline
- Start date
- 2008-12-16
- Primary completion
- 2009-09-29
- Completion
- 2009-09-29
- First posted
- 2008-12-19
- Last updated
- 2020-10-19
Locations
12 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00811499. Inclusion in this directory is not an endorsement.